Accurately assessing treatment response in PV and deciding when to switch therapies

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses how to assess treatment response in patients with polycythemia vera (PV) and when to switch the patient to another therapeutic option. Dr Masarova outlines the criteria for evaluating a patient's response, highlighting the need for controlled blood counts and a lack of regular phlebotomies. While there are some warning signs suggestive of suboptimal response, Dr Masarova emphasizes that determining true treatment failure requires careful evaluation, and patients who do not respond to front-line therapy should be referred to a myeloproliferative neoplasm (MPN) specialist, as underdosing or comorbidities may be responsible for the lack of response. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.